Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004590 | 0.93 | TRPV1 (0.33) | TACR1NAA50CACNA1HCACNA1CTRPV1 | |
| SCHEMBL4871010 | 0.91 | NR1H2 (0.34) | TACR1NR1H2NR1H3NAA50 | |
| SCHEMBL6004473 | 0.91 | NR1H2 (0.36) | TACR1NR1H2NR1H3 | |
| SCHEMBL6004899 | 0.90 | NR1H2 (0.36) | TACR1NR1H2NR1H3 | |
| SCHEMBL6005072 | 0.87 | NR1H2 (0.37) | TACR1NR1H2NR1H3 | |
| SCHEMBL6002684 | 0.78 | TACR1 (0.36) | TACR1NR1H2NR1H3TRPV1PIM1 | |
| SCHEMBL6004017 | 0.75 | MMP13 (0.42) | NR1H2NR1H3 | |
| SCHEMBL4832492 | 0.74 | TACR1 (0.35) | TACR1NR1H2NR1H3TRPV1 | |
| SCHEMBL6004594 | 0.73 | AADAT (0.30) | — | |
| SCHEMBL4899277 | 0.69 | CD38 (0.35) | TACR1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | TACR1 3601/4885NR1H2 744/4885NR1H3 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.